These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34748151)

  • 1. Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis.
    Valeriani M; Detti B; Fodor A; Caini S; Borghesi S; Trippa F; Triggiani L; Bruni A; Russo D; Saldi S; Di Staso M; Francolini G; Lancia A; Marinelli L; Di Muzio N; Aristei C; Livi L; Magrini SM; Ingrosso G
    Radiol Med; 2022 Jan; 127(1):108-116. PubMed ID: 34748151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy.
    Ingrosso G; Detti B; Fodor A; Caini S; Borghesi S; Triggiani L; Trippa F; Russo D; Bruni A; Francolini G; Lancia A; Marinelli L; Di Muzio N; Livi L; Magrini SM; Maranzano E; Musio D; Aristei C; Valeriani M
    Clin Transl Oncol; 2021 Aug; 23(8):1577-1584. PubMed ID: 33495981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience.
    Valeriani M; Marinelli L; Macrini S; Reverberi C; Aschelter AM; De Sanctis V; Marchetti P; Tronnolone L; Osti MF
    Radiat Oncol; 2019 Nov; 14(1):205. PubMed ID: 31727093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
    Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.
    Nikitas J; Castellanos Rieger A; Farolfi A; Seyedroudbari A; Kishan AU; Nickols NG; Steinberg ML; Valle LF; Rettig M; Czernin J; Calais J
    J Nucl Med; 2024 Sep; 65(9):1387-1394. PubMed ID: 39089811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial.
    Rans K; Joniau S; Berghen C; Goffin K; Dumez H; Haustermans K; De Meerleer G
    Eur Urol Oncol; 2024 Dec; 7(6):1441-1450. PubMed ID: 38664137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic radiotherapy to oligoprogressive lesions detected with
    Onal C; Ozyigit G; Oymak E; Guler OC; Tilki B; Hurmuz P; Akyol F
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3683-3692. PubMed ID: 33693965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
    Sayegh N; Tripathi N; Nussenzveig RH; Thomas VM; Tandar C; Goel D; Nordblad B; Sahu KK; Li H; L Maughan B; Agarwal N; Swami U
    Eur Urol Focus; 2023 Jan; 9(1):106-109. PubMed ID: 35835693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
    Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
    Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
    Mori K; Kimura T; Ito K; Onuma H; Tanaka M; Matsuura T; Kurokawa G; Iwatani K; Inaba Y; Sakanaka K; Sasaki H; Miki J; Shimomura T; Miki K; Egawa S
    Prostate; 2018 Jul; 78(10):766-772. PubMed ID: 29635810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials.
    Pezzulla D; Macchia G; Cilla S; Buwenge M; Ferro M; Bonome P; Romano C; Zamagni A; Valentini V; Morganti AG; Deodato F
    Clin Exp Metastasis; 2021 Dec; 38(6):519-526. PubMed ID: 34651242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
    Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
    Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR).
    Valero J; Peleteiro P; Henríquez I; Conde A; Piquer T; Lozano A; Soler CC; Muñoz J; Illescas A; Jove J; Flores MM; Baquedano J; Diezhandino P; de Celis RP; Pardo EH; Samper P; Villoslada I; Eguiguren M; Millan V
    Clin Transl Oncol; 2020 Aug; 22(8):1378-1389. PubMed ID: 31989474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide.
    La Vecchia M; Fazio I; Borsellino N; Lo Casto A; Galanti D
    Tumori; 2023 Aug; 109(4):413-417. PubMed ID: 36358013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
    Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
    J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer.
    Berghen C; Joniau S; Ost P; Poels K; Everaerts W; Decaestecker K; Haustermans K; Devos G; De Meerleer G
    Eur Urol Oncol; 2021 Apr; 4(2):305-309. PubMed ID: 31558422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer.
    Massaro M; Facondo G; Vullo G; Aschelter AM; Rossi A; De Sanctis V; Marchetti P; Osti MF; Valeriani M
    Front Oncol; 2021; 11():695136. PubMed ID: 34631527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection.
    Franzese C; Perrino M; Marzo MA; Badalamenti M; Baldaccini D; D'Agostino G; Marini B; De Vincenzo F; Zucali PA; Scorsetti M
    Clin Exp Metastasis; 2022 Jun; 39(3):449-457. PubMed ID: 35190933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
    Lohaus F; Zöphel K; Löck S; Wirth M; Kotzerke J; Krause M; Baumann M; Troost EGC; Hölscher T
    Eur Urol; 2019 Apr; 75(4):548-551. PubMed ID: 30578119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice.
    Patel PH; Tunariu N; Levine DS; de Bono JS; Eeles RA; Khoo V; Murray J; Parker CC; Pathmanathan A; Reid A; van As N; Tree AC
    Front Oncol; 2022; 12():862995. PubMed ID: 35656509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.